1
|
Seino S, Ikehata H, Tanabe M, Umeda T, Tomiyama T, Tanaka A, Furubayashi T, Sakane T, Kiwa T, Washino M, Nomura K, Tonooka S, Izawa A, Okumura Y, Nakagawa T. Investigating the efficacy of nasal administration for delivering magnetic nanoparticles into the brain for magnetic particle imaging. J Control Release 2024; 367:515-521. [PMID: 38237689 DOI: 10.1016/j.jconrel.2024.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 11/24/2023] [Accepted: 01/14/2024] [Indexed: 02/06/2024]
Abstract
This study explored the effectiveness of nasal administration in delivering magnetic nanoparticles into the brain for magnetic particle imaging of target regions. Successful delivery of iron oxide nanoparticles, which serve as contrast agents, to specific sites within the brain is crucial for achieving magnetic particle imaging. Nasal administration has gained attention as a method to bypass the blood-brain barrier and directly deliver therapeutics to the brain. In this study, we investigated surface modification techniques for administering magnetic nanoparticles into the nasal cavity, and provided experimental validation through in vivo studies. By compositing magnetic nanoparticles with gold nanoparticles, we enabled additional surface modification via AuS bonds without compromising their magnetic properties. The migration of the designed PEGylated magnetic nanoparticles into the brain following nasal administration was confirmed by magnetization measurements. Furthermore, we demonstrated the accumulation of these nanoparticles at specific target sites using probe molecules immobilized on the PEG terminus. Thus, the efficacy of delivering magnetic nanoparticles to the brain via nasal administration was demonstrated in this study. The findings of this research are expected to contribute significantly to the realization of magnetic particle imaging of target regions within the brain.
Collapse
Affiliation(s)
- Satoshi Seino
- Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
| | - Hiroto Ikehata
- Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Mizuki Tanabe
- Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Tomohiro Umeda
- Department of Translational Neuroscience, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahimachi, Abeno-ku, Osaka City, Osaka 545-8585, Japan
| | - Takami Tomiyama
- Department of Translational Neuroscience, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahimachi, Abeno-ku, Osaka City, Osaka 545-8585, Japan
| | - Akiko Tanaka
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada, Kobe 658-8558, Japan
| | - Tomoyuki Furubayashi
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada, Kobe 658-8558, Japan
| | - Toshiyasu Sakane
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada, Kobe 658-8558, Japan
| | - Toshihiko Kiwa
- Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 3-1-1,Tsushima-Naka, Kitaku,Okayama 700-8530, Japan
| | - Masaomi Washino
- Advanced Technology R&D Center, Mitsubishi Electric Corp., 8 - 1 - 1, Tsukaguchi-Honmachi, Amagasaki, Hyogo 661-8661, Japan
| | - Kota Nomura
- Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Advanced Technology R&D Center, Mitsubishi Electric Corp., 8 - 1 - 1, Tsukaguchi-Honmachi, Amagasaki, Hyogo 661-8661, Japan
| | - Shun Tonooka
- Advanced Technology R&D Center, Mitsubishi Electric Corp., 8 - 1 - 1, Tsukaguchi-Honmachi, Amagasaki, Hyogo 661-8661, Japan
| | - Akihiro Izawa
- BD&IP Dept., Nihon Medi-Physics Co., Ltd., 3-4-10, Shinsuna, Koto-ku, Tokyo 136-0075, Japan
| | - Yuki Okumura
- Research Center, Nihon Medi-Physics Co., Ltd., 3-1, Kitasode, Sodegaura City, Chiba 299-0266, Japan
| | - Takashi Nakagawa
- Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| |
Collapse
|
2
|
Tanabe M, Denda T, Natori T, Horiuchi K, Sakaguchi K, Koide S, Nagano Y, Nagano N. Commonality of multispecies GES carbapenemase-producing organisms in hospital wastewater with those in previously investigated epidemiologically linked municipal wastewater influents. J Glob Antimicrob Resist 2024; 36:139-141. [PMID: 38154748 DOI: 10.1016/j.jgar.2023.12.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 12/14/2023] [Accepted: 12/21/2023] [Indexed: 12/30/2023] Open
Affiliation(s)
- Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tatsuya Natori
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Kazuki Horiuchi
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Kanae Sakaguchi
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan; Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan.
| |
Collapse
|
3
|
Denda T, Natori T, Tanabe M, Horiuchi K, Koide S, Nagano Y, Nagano N. Comparative analysis of bla NDM-1-carrying plasmids harboured by four different Acinetobacter species from hospital environments and patients during 2018-2022. J Glob Antimicrob Resist 2024; 36:62-64. [PMID: 38122984 DOI: 10.1016/j.jgar.2023.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 08/26/2023] [Accepted: 12/07/2023] [Indexed: 12/23/2023] Open
Affiliation(s)
- Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tatsuya Natori
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Kazuki Horiuchi
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan; Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan.
| |
Collapse
|
4
|
Tanabe M, Sugawara Y, Denda T, Sakaguchi K, Takizawa S, Koide S, Hayashi W, Yu L, Kayama S, Sugai M, Nagano Y, Nagano N. Municipal wastewater monitoring revealed the predominance of bla GES genes with diverse variants among carbapenemase-producing organisms: high occurrence and persistence of Aeromonas caviae harboring the new bla GES variant bla GES-48. Microbiol Spectr 2023; 11:e0218823. [PMID: 37811969 PMCID: PMC10715227 DOI: 10.1128/spectrum.02188-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 08/22/2023] [Indexed: 10/10/2023] Open
Abstract
IMPORTANCE The emergence and spread of carbapenemase-producing organisms (CPOs) represent a global health threat because they are associated with limited treatment options and poor clinical outcomes. Wastewater is considered a hotspot for the evolution and dissemination of antimicrobial resistance. Thus, analyses of municipal wastewater are critical for understanding the circulation of these CPOs and carbapenemase genes in local communities, which remains scarcely known in Japan. This study resulted in several key observations: (i) the vast majority of bla GES genes, including six new bla GES variants, and less frequent bla IMP genes were carbapenemase genes encountered exclusively in wastewater influent; (ii) the most dominant CPO species were Aeromonas spp., in which a remarkable diversity of new sequence types was observed; and (iii) CPOs were detected from combined sewer wastewater, but not from separate sewer wastewater, suggesting that the load of CPOs from unrecognized environmental sources could greatly contribute to their detection in influent wastewater.
Collapse
Affiliation(s)
- Mizuki Tanabe
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
| | - Yo Sugawara
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
| | - Kanae Sakaguchi
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
| | - Shino Takizawa
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University, Graduate School of Medicine, Science and Technology, Matsumoto, Nagano, Japan
| | - Wataru Hayashi
- Department of Medical Sciences, Shinshu University, Graduate School of Medicine, Science and Technology, Matsumoto, Nagano, Japan
| | - Liansheng Yu
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan
| | - Shizuo Kayama
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan
| | - Motoyuki Sugai
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
- Department of Medical Sciences, Shinshu University, Graduate School of Medicine, Science and Technology, Matsumoto, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Graduate School of Medicine, Shinshu University, Matsumoto, Nagano, Japan
- Department of Medical Sciences, Shinshu University, Graduate School of Medicine, Science and Technology, Matsumoto, Nagano, Japan
| |
Collapse
|
5
|
Tanabe M, Natori T, Denda T, Horiuchi K, Koide S, Nagano Y, Nagano N. A novel blaNDM-1-carrying multidrug-resistant genomic island GIMmSU8481 in a faecal Morganella morganii subsp. sibonii isolate from a patient. J Glob Antimicrob Resist 2023; 35:322-324. [PMID: 37918786 DOI: 10.1016/j.jgar.2023.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 10/27/2023] [Indexed: 11/04/2023] Open
Affiliation(s)
- Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tatsuya Natori
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Kazuki Horiuchi
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan; Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan.
| |
Collapse
|
6
|
Sakaguchi K, Tanabe M, Takizawa S, Kasahara S, Denda T, Koide S, Hayashi W, Nagano Y, Nagano N. Zoonotic potential and antimicrobial resistance of Escherichia spp. in urban crows in Japan-first detection of E. marmotae and E. ruysiae. Comp Immunol Microbiol Infect Dis 2023; 100:102040. [PMID: 37619490 DOI: 10.1016/j.cimid.2023.102040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/26/2023]
Abstract
Little is known about the prevalence of antimicrobial-resistant bacteria and pathogenic Escherichia coli in crows (carrion and jungle crows). We studied the phylogeny, virulence and antimicrobial resistance gene profiles of crow E. coli isolates to investigate their zoonotic potential and molecular epidemiology. During the winter of 2021-2022, 34 putative E. coli isolates were recovered from 27 of the 65 fresh fecal samples collected in urban areas. Three strains of the B1-O88:H8-ST446-fimH54 lineage, classified as extraintestinal pathogenic E. coli (ExPEC) and necrotoxigenic E. coli type 2, were colistin-resistant and harbored mcr-1.1-carrying IncI2 plasmids. The blaCTX-M-55 was identified in a multidrug-resistant B1-O non-typeable:H23-ST224-fimH39 strain. In phylogroup B2, two lineages of O6:H1-ST73-fimH30 and O6:H5-ST83-fimH21 were classified as ExPEC, uropathogenic E. coli, and necrotoxigenic E. coli type 1 (O6:H5-ST83-fimH21), and contained several virulence genes associated with avian pathogenic E. coli. Noteworthy is that three isolates, identified as E. coli by MALDI-TOF MS, were confirmed to be two Escherichia marmotae (cryptic clade V) and one Escherichia ruysiae (cryptic clade III) based on ANI and dDDH analyses. Our results provide the first evidence of these new species in crows. E. marmotae and E. ruysiae isolates in this study were classified as ExPEC and contained the enteroaggregative E. coli heat-stable toxin 1 gene. In addition, these two E. marmotae isolates displayed a close genetic relationship with human isolates associated with septicemia. This study provides the first insights into the prevalence and zoonotic significance of Escherichia spp. in urban crows in Japan, posing a significant risk for their transmission to humans.
Collapse
Affiliation(s)
- Kanae Sakaguchi
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Shino Takizawa
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Satoe Kasahara
- Suwa Hydrobiological Station, Faculty of Science, Shinshu University, 5-2-4 Kogan-dori, Suwa, Nagano 392-0027, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Wataru Hayashi
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
| |
Collapse
|
7
|
Tanabe M, Natori T, Horiuchi K, Denda T, Koide S, Nagano Y, Nagano N. Novel genomic island carrying a new vanD allele in a vancomycin-resistant Enterococcus faecium clinical isolate belonging to clade A1 in Japan. J Glob Antimicrob Resist 2023; 34:211-213. [PMID: 37527703 DOI: 10.1016/j.jgar.2023.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/22/2023] [Accepted: 07/25/2023] [Indexed: 08/03/2023] Open
Affiliation(s)
- Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tatsuya Natori
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Kazuki Horiuchi
- Department of Laboratory Medicine, Shinshu University Hospital, Nagano, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan; Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, Nagano, Japan.
| |
Collapse
|
8
|
Fujiyoshi MRA, Fujiyoshi Y, Gimpaya N, Bechara R, Jeyalingam T, Calo NC, Forbes N, Khan R, Atalla M, Toshimori A, Shimamura Y, Tanabe M, Mosko J, Inoue H, Grover S. A114 UNIFIED MAGNIFYING ENDOSCOPIC CLASSIFICATION (UMEC) FOR GASTROINTESTINAL LESIONS: A NORTH AMERICAN EDUCATION STUDY. J Can Assoc Gastroenterol 2023. [PMCID: PMC9991233 DOI: 10.1093/jcag/gwac036.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
Abstract
Abstract
Background
Magnification endoscopy and magnification narrow-band imaging are image enhanced endoscopy technologies that may allow for the diagnosis of advanced neoplasia in the GI tract on the basis of imaging characteristics. Recently, the Unified Magnifying Endoscopic Classification (UMEC) has been developed, which unified the criteria for the esophagus, stomach, and colon. UMEC divides optical diagnosis into one of the three categories: non-neoplastic, intramucosal neoplasia, and deep submucosal invasive cancer.
Purpose
The objective of this study is to educate North American endoscopists on the use of the UMEC schema, and to ascertain performance of the UMEC framework among North American endoscopists.
Method
Using UMEC, five North American endoscopists (>1000 procedures) without prior training in magnifying endoscopy independently diagnosed previously collected endoscopic image set of the esophagus, stomach, and colon. The endoscopists were trained on the use of UMEC via an eleven-minute training video with exemplars of each element of UMEC from esophagus, stomach, and colon. All endoscopists were blinded to white-light and non-magnifying NBI findings as well as histopathological diagnosis. The diagnostic performance of UMEC was assessed while using the gold standard histopathology as a reference.
Result(s)
A total of 299 gastrointestinal lesions (77 esophagus, 92 stomach, and 130 colon) were assessed using UMEC. For esophageal squamous cell carcinoma, the sensitivity, specificity, and accuracy for all 5 endoscopists ranged from 65.2% (95% CI: 50.9–77.9) to 87.0% (95% CI: 75.3–94.6), 77.4% (95% CI: 60.9–89.6) to 96.8% (95% CI: 86.8–99.8), and 75.3% to 87.0%, respectively. For gastric adenocarcinoma, the sensitivity, specificity, and accuracy for all 5 endoscopists ranged from 94.9% (95% CI: 85.0–99.1) to 100%, 52.9% (95% CI: 39.4–66.2) to 92.2% (95% CI: 82.7–97.5), and 73.3% to 93.3%, respectively. For colorectal adenocarcinoma, the sensitivity, specificity, and accuracy for all 5 endoscopists ranged from 76.2% (95% CI: 62.0–87.3) to 83.3% (95% CI: 70.3–92.5), 89.7% (95% CI: 82.1–94.9) to 97.7% (95% CI: 93.1–99.6), and 86.8% to 90.7%, respectively.
Image
Conclusion(s)
UMEC is a simple and practical classification that can be used to introduce and educate endoscopists to magnification narrow-band imaging and optical diagnosis.
Please acknowledge all funding agencies by checking the applicable boxes below
CAG
Disclosure of Interest
M. R. A. Fujiyoshi Grant / Research support from: 2022 CAG/AbbVie Education Research Grant, Y. Fujiyoshi: None Declared, N. Gimpaya: None Declared, R. Bechara: None Declared, T. Jeyalingam: None Declared, N. Calo: None Declared, N. Forbes: None Declared, R. Khan: None Declared, M. Atalla: None Declared, A. Toshimori: None Declared, Y. Shimamura: None Declared, M. Tanabe: None Declared, J. Mosko: None Declared, H. Inoue: None Declared, S. Grover: None Declared
Collapse
Affiliation(s)
- M R A Fujiyoshi
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - Y Fujiyoshi
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - N Gimpaya
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
| | - R Bechara
- Division of Gastroenterology, Kingston General and Hotel Dieu Hospital, Queen's University , Kingston
| | - T Jeyalingam
- Division of Gastroenterology, University Health Network, University of Toronto , Toronto
| | - N C Calo
- Division of Gastroenterology, University of Ottawa , Ottawa
| | - N Forbes
- Division of Gastroenterology, University of Calgary , Calgary , Canada
| | - R Khan
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
| | - M Atalla
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
| | - A Toshimori
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - Y Shimamura
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - M Tanabe
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - J Mosko
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
| | - H Inoue
- Digestive Diseases Center, Showa University Koto Toyosu Hospital , Tokyo , Japan
| | - S Grover
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto , Toronto , Canada
| |
Collapse
|
9
|
Soga E, Sakaguchi K, Takizawa S, Tanabe M, Denda T, Koide S, Hayashi W, Kasahara S, Nagano Y, Nagano N. Emergence of Vibrio cincinnatiensis, a Rare Human Pathogen, in Urban Crows. Microbiol Spectr 2023; 11:e0392522. [PMID: 36475968 PMCID: PMC9927279 DOI: 10.1128/spectrum.03925-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Eiji Soga
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Kanae Sakaguchi
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Shino Takizawa
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Mizuki Tanabe
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Tomohiro Denda
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Shota Koide
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science, and Technology, Nagano, Japan
| | - Wataru Hayashi
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science, and Technology, Nagano, Japan
| | - Satoe Kasahara
- Suwa Hydrobiological Station, Faculty of Science, Shinshu University, Nagano, Japan
| | - Yukiko Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
| | - Noriyuki Nagano
- Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan
- Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science, and Technology, Nagano, Japan
| |
Collapse
|
10
|
Uno K, Koike T, Hatta W, Saito M, Tanabe M, Masamune A. Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia. Diagnostics (Basel) 2022; 12:2437. [PMID: 36292126 PMCID: PMC9600913 DOI: 10.3390/diagnostics12102437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 10/04/2022] [Indexed: 11/17/2022] Open
Abstract
Barrett esophagus (BE) is a precursor to a life-threatening esophageal adenocarcinoma (EAC). Surveillance endoscopy with random biopsies is recommended for early intervention against EAC, but its adherence in the clinical setting is poor. Dysplastic lesions with flat architecture and patchy distribution in BE are hardly detected by high-resolution endoscopy, and the surveillance protocol entails issues of time and labor and suboptimal interobserver agreement for diagnosing dysplasia. Therefore, the development of advanced imaging technologies is necessary for Barrett's surveillance. Recently, non-endoscopic or endoscopic technologies, such as cytosponge, endocytoscopy, confocal laser endomicroscopy, autofluorescence imaging, and optical coherence tomography/volumetric laser endomicroscopy, were developed, but most of them are not clinically available due to the limited view field, expense of the equipment, and significant time for the learning curve. Another strategy is focused on the development of molecular biomarkers, which are also not ready to use. However, a combination of advanced imaging techniques together with specific biomarkers is expected to identify morphological abnormalities and biological disorders at an early stage in the surveillance. Here, we review recent developments in advanced imaging and molecular imaging for Barrett's neoplasia. Further developments in multiple biomarker panels specific for Barrett's HGD/EAC include wide-field imaging systems for targeting 'red flags', a high-resolution imaging system for optical biopsy, and a computer-aided diagnosis system with artificial intelligence, all of which enable a real-time and accurate diagnosis of dysplastic BE in Barrett's surveillance and provide information for precision medicine.
Collapse
Affiliation(s)
- Kaname Uno
- Division of Gastroenterology, Tohoku University Hospital, Sendai 981-8574, Japan
| | | | | | | | | | | |
Collapse
|
11
|
Takasaki A, Kurita T, Yanagisawa M, Ino A, Hiramatsu D, Ikmi A, Ito H, Kato T, Fukuoka S, Sugimoto T, Nakata T, Masuda J, Tanabe M, Kakimoto H, Dohi K. Impact of in-hospital medical management for COVID-19 pandemic on door-to-balloon time in patients with ST-elevation myocardial infarction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Delayed door-to-balloon (DTB) time and deterioration of in-hospital mortality during the coronavirus disease 2019 (COVID-19) pandemic have been reported. Little is known about the impact of changes in in-hospital medical management before primary percutaneous coronary intervention (PCI) for COVID-19 such as screening test (antigen or polymerase chain reaction (PCR) tests, chest CT for excluding the pneumoniae) and primary PCI under full personal protective equipment (PPE) on DTB time and in-hospital mortality.
Purpose
The purpose of this study was to evaluate the impact of in-hospital medical management for COVID-19 on DTB time and in-hospital mortality during COVID-19 pandemic period.
Methods
We compared DTB time and in-hospital mortality of 502 ST-elevation myocardial infarction (STEMI) patients during COVID-19 pandemic (February 2020 and January 2021) with 2035 STEMI patients before pandemic (February 2016 and January 2020) using date from Mie ACS registry, a retrospective and multicenter registry.
Results
The COVID-19 screening tests before primary PCI and/or primary PCI under full PPE was performed on 173/502 (34.5%) patients (antigen or PCR tests; 39 (7.8%), chest CT; 156 (31.3%), full PPE; 11 (2.2%)). These patients had lower rate of achievement of DTB time ≤90 min compared with others (Figure 1A). Moreover, In-hospital management of COVID-19 screening tests and/or primary PCI under full PPE was an independent factor of DTB time>90 min with odds ratio of 1.94 (95% confidential interval: 1.37–2.76, p<0.001). In addition, in-hospital mortality of those patients was higher compared with others (Figure 1B).
Conclusion
In-hospital medical management for COVID-19 screening tests before primary PCI and/or primary PCI under full PPE was the independent factor of DTB time>90 min. This study reinforces the need to focus efforts on shortening DTB time, while controlling the epidemic of infection.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - T Kurita
- Mie University Hospital , Tsu , Japan
| | | | - A Ino
- Ise City Red Cross Hospital, cardiology , Ise , Japan
| | - D Hiramatsu
- Matsusaka chuo general hospital , matsusaka , Japan
| | - A Ikmi
- Suzuka chuo general hospital , Suzuka , Japan
| | - H Ito
- Mie University Hospital , Tsu , Japan
| | - T Kato
- Mie prefectural general medical center , yokkaichi , Japan
| | - S Fukuoka
- mie chuo medical center , tsu , Japan
| | | | | | - J Masuda
- Mie prefectural general medical center , yokkaichi , Japan
| | - M Tanabe
- Mie University Hospital , Tsu , Japan
| | - H Kakimoto
- saiseikai matsusaka general hospital , matsusaka , Japan
| | - K Dohi
- Mie University Hospital , Tsu , Japan
| |
Collapse
|
12
|
Konishi T, Fujiogi M, Michihata N, Tanaka-Mizutani H, Morita K, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Breast cancer surgery in patients with schizophrenia: short-term outcomes from a nationwide cohort. Br J Surg 2021; 108:168-173. [PMID: 33711128 DOI: 10.1093/bjs/znaa070] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 07/04/2020] [Accepted: 09/30/2020] [Indexed: 01/25/2023]
Abstract
BACKGROUND Although patients with schizophrenia have a higher risk of developing breast cancer than the general population, studies that have investigated postoperative complications after breast cancer surgery in patients with schizophrenia are scarce. This study examined associations between schizophrenia and short-term outcomes following breast cancer surgery. METHODS Patients who underwent surgery for stage 0-III breast cancer between July 2010 and March 2017 were identified from a Japanese nationwide inpatient database. Multivariable analyses were conducted to compare postoperative complications and hospitalization costs between patients with schizophrenia and those without any psychiatric disorder. Three sensitivity analyses were performed: a 1 : 4 matched-pair cohort analysis with matching for age, institution, and fiscal year at admission; analyses excluding patients with schizophrenia who were not taking antipsychotic medication; and analyses excluding patients with schizophrenia who were admitted to hospital involuntarily. RESULTS The study included 3660 patients with schizophrenia and 350 860 without any psychiatric disorder. Patients with schizophrenia had a higher in-hospital morbidity (odds ratio (OR) 1.37, 95 per cent c.i. 1.21 to 1.55), with more postoperative bleeding (OR 1.34, 1.05 to 1.71) surgical-site infections (OR 1.22, 1.04 to 1.43), and sepsis (OR 1.20, 1.03 to 1.41). The total cost of hospitalization (coefficient €743, 95 per cent c.i. 680 to 806) was higher than that for patients without any psychiatric disorder. All sensitivity analyses showed similar results to the main analyses. CONCLUSION Although causal inferences remain premature, multivariable regression analyses showed that schizophrenia was associated with greater in-hospital morbidity and higher total cost of hospitalization after breast cancer surgery than in the general population.
Collapse
Affiliation(s)
- T Konishi
- Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.,Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan
| | - M Fujiogi
- Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan
| | - N Michihata
- Department of Health Services Research, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - H Tanaka-Mizutani
- Department of Neuropsychiatry, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - K Morita
- Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan.,Department of Health Services, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - H Matsui
- Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan
| | - K Fushimi
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
| | - M Tanabe
- Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Y Seto
- Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.,Department of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - H Yasunaga
- Department of Clinical Epidemiology and Health Economics, School of Public Health, University of Tokyo, Tokyo, Japan
| |
Collapse
|
13
|
Sato A, Tanabe M, Tsuboi Y, Ito Y, Akiyama F, Takahashi S, Murakami Y, Seto Y. PIK3CA mutations and predicting the therapeutic effects of neoadjuvant chemotherapy in primary breast cancer. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30720-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Morise Z, Aldrighetti L, Belli G, Ratti F, Belli A, Cherqui D, Tanabe M, Wakabayashi G. Laparoscopic repeat liver resection for hepatocellular carcinoma: a multicentre propensity score-based study. Br J Surg 2020; 107:889-895. [PMID: 31994182 DOI: 10.1002/bjs.11436] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 09/08/2019] [Accepted: 10/28/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND In the absence of randomized controlled data and even propensity-matched data, indications for, and outcomes of, laparoscopic repeat liver resection for hepatocellular carcinoma (HCC) remain uncertain. This study aimed to clarify the current indications for laparoscopic repeat liver resection for HCC, and to evaluate outcomes. METHODS Forty-two liver surgery centres around the world registered patients who underwent repeat liver resection for HCC. Patient characteristics, preoperative liver function, tumour characteristics, surgical method, and short- and long-term outcomes were recorded. RESULTS Analyses showed that the laparoscopic procedure was generally used in patients with relatively poor performance status and liver function, but favourable tumour characteristics. Intraoperative blood loss (mean(s.d.) 254(551) versus 748(1128) ml; P < 0·001), duration of operation (248(156) versus 285(167) min; P < 0·001), morbidity (12·7 versus 18·1 per cent; P = 0·006) and duration of postoperative hospital stay (10·1(14·3) versus 11·8(11·8) days; P = 0·013) were significantly reduced for laparoscopic compared with open procedures, whereas survival time was comparable (median 10·04 versus 8·94 years; P = 0·297). Propensity score matching showed that laparoscopic repeat liver resection for HCC resulted in less intraoperative blood loss (268(730) versus 497(784) ml; P = 0·001) and a longer operation time (272(187) versus 232(129); P = 0·007) than the open approach, and similar survival time (12·55 versus 8·94 years; P = 0·086). CONCLUSION Laparoscopic repeat liver resection is feasible in selected patients with recurrent HCC.
Collapse
Affiliation(s)
- Z Morise
- Department of General Surgery, Fujita Health University School of Medicine, Bantane Hospital, Aichi, Japan
| | - L Aldrighetti
- Hepatobiliary Division, Department of Surgery, San Raffaele Hospital, Milan, Italy
| | - G Belli
- Department of General and Hepatopancreatobiliary Surgery, Loreto Nuovo Hospital, Naples, Italy
| | - F Ratti
- Hepatobiliary Division, Department of Surgery, San Raffaele Hospital, Milan, Italy
| | - A Belli
- Department of Abdominal Surgical Oncology, Fondazione G. Pascale-Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute of Naples, Naples, Italy
| | - D Cherqui
- Hepatobiliary Centre, Paul Brousse Hospital, Villejuif, France
| | - M Tanabe
- Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - G Wakabayashi
- Department of Surgery, Ageo Central General Hospital, Ageo, Japan
| | | |
Collapse
|
15
|
Horimoto Y, Terao T, Tsutsumi Y, Tanabe M, Mogushi K, Arakawa A, Sonoue H, Saito M. Elucidation of frequent HER2 overexpression in ductal carcinoma in situ. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30618-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Sakuta K, Sato T, Tanabe M, Higa H, Ikeda M, Matsuno H, Komatsu T, Sakai K, Terasawa Y, Omoto S, Mitsumura H, Toyoda C, Iguchi Y. The NAG scale: A noble predictive scale for hematoma expansion in non-severe intracerebral hemorrhage patients. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Matsuno S, Yamane M, Muramatsu T, Okamura A, Kashima Y, Sakurada M, Kijima M, Tanabe M, Mutoh M, Habara M. P4220Feasibility of contemporary percutaneous coronary intervention for chronic total occlusion in chronic kidney disease patients: sub-analysis of Japanese multicenter registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S. Matsuno
- Cardiovascular Institute, Dept. of Cardiovascular Medicine, Tokyo, Japan
| | - M. Yamane
- Saitama Sekishinkai Hospital, Cardiology Department, Saitama, Japan
| | - T. Muramatsu
- Tokyo General Hospital, Cardiovascular Center, Tokyo, Japan
| | - A. Okamura
- Sakurabashi-Watanabe Hospital, Division of Cardiology, Osaka, Japan
| | - Y. Kashima
- Sapporo CardioVascular Clinic, Division of Cardiology, Hokkaido, Japan
| | - M. Sakurada
- Tokorozawa Heart Center, Dept. of Cardiology, Saitama, Japan
| | - M. Kijima
- Hoshi General Hospital, Cardiology and Vascular Medicine, Fukushima, Japan
| | - M. Tanabe
- Kyoto Okamoto Memorial Hospital, Dept. of Cardiology, Kyoto, Japan
| | - M. Mutoh
- Saitama Prefecture Cardiovascular and Respiratory Center, Division of Cardiology, Saitama, Japan
| | - M. Habara
- Toyohashi Heart Center, Dept. of Cardiology, Aichi, Japan
| | | |
Collapse
|
18
|
Katoh H, Yamane M, Muramatsu T, Okamura A, Kashima Y, Matsuno S, Sakurada M, Kijima M, Tanabe M, Habara M. P4222Examination of chronic total occlusion cases who were switched to antegrade approach after failure of retrograde procedure from the Japanese Retrograde Summit Registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Shimazu M, Kato Y, Kawachi S, Tanabe M, Hoshino K, Wakabayashi G, Kitagawa Y, Kitajima M. Impact of Portal Hemodynamic Changes in Partial Liver Grafts on Short-Term Graft Regeneration in Living Donor Liver Transplantation. Transplant Proc 2017; 48:2747-2755. [PMID: 27788812 DOI: 10.1016/j.transproceed.2016.06.053] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Revised: 05/20/2016] [Accepted: 06/22/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Regeneration of partial liver grafts is critical for successful living donor liver transplantation (LDLT), especially in adult recipients. The purpose of this study was to investigate the intraoperative hemodynamic changes in partial liver grafts and characterize their potential impact on post-transplant liver regeneration in LDLT. METHODS We examined the portal venous flow (PVF) and hepatic arterial flow (HAF) to partial liver grafts by means of ultrasonic transit time flowmeter of donors immediately before graft retrieval and of the corresponding recipients after vascular reconstruction in 48 LDLT cases. We evaluated post-transplant liver regeneration according to the changes in graft liver volume between the time of transplantation and the 7th post-transplant day. RESULTS There was a significant increase in PVF to the partial liver grafts in recipients (rPVF) compared with that in donors. In contrast, graft HAF in recipients significantly decreased compared with that in donors. The rPVF inversely correlated with graft weight (GW)-recipient body weight ratio (GRWR), whereas HAF volume showed no significant correlation. The rPVF/GW positively correlated with the rate of liver regeneration (GRR), which inversely correlated with GRWR. The rPVF/GW was significantly higher, and GRR tended to be larger in the small graft group than in the non-small graft group. CONCLUSIONS Intraoperative portal hemodynamic changes in partial liver grafts strongly affect their post-transplant regeneration. In particular, in small liver grafts, an immediate and remarkable increase in graft PVF may contribute to rapid liver regeneration after LDLT if the increased PVF remains within a safe range.
Collapse
Affiliation(s)
- M Shimazu
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan; Department of Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
| | - Y Kato
- Department of Surgery, Fujita Health University, Aichi, Japan
| | - S Kawachi
- Department of Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - M Tanabe
- Department of Surgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - K Hoshino
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - G Wakabayashi
- Department of Surgery, Ageo Central General Hospital, Saitama, Japan
| | - Y Kitagawa
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - M Kitajima
- International University of Health and Welfare, Tokyo, Japan
| |
Collapse
|
20
|
Tanabe M, Niwa K, Kinoshita K. Absolute optical responsivity down to the photon counting level with a photomultiplier tube. Rev Sci Instrum 2017; 88:043104. [PMID: 28456233 DOI: 10.1063/1.4979812] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
A novel method is presented for evaluation of the absolute optical responsivity of a photomultiplier tube (PMT) at optical powers down to the photon counting level under visible light. This method is based on a combination of the calibrated responsivity and nonlinearity corrections using a silicon photodiode and a PMT. The evaluation results with the PMT enable accurate determination of the absolute optical responsivity over a wide power range of 10-11 W to 10-16 W under visible light. This method provides validation of both the photon counting efficiency of a PMT and of accurate optical measurement with attenuators at the photon counting level.
Collapse
Affiliation(s)
- M Tanabe
- National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology, Umesono 1-1-1, Tsukuba, Ibaraki 3058563, Japan
| | - K Niwa
- National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology, Umesono 1-1-1, Tsukuba, Ibaraki 3058563, Japan
| | - K Kinoshita
- National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology, Umesono 1-1-1, Tsukuba, Ibaraki 3058563, Japan
| |
Collapse
|
21
|
Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P5-16-04: A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: This study aimed to evaluate response to neoadjuvant chemotherapy (NAC) for patients with hormone receptor-negative (HR-negative) breast cancer (BC) to identify subtypes that require anthracycline treatment.
Methods: In total, 103 patients with operable HR-negative BC were registered. They were randomely assigned to administration of 6 cycles of docetaxel (75mg/m2) and cyclophosphamide (600 mg/m2) (TC6) or 3 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100mg/m2), and cyclophosphamide (500mg/m2) followed by 3 cycles of docetaxel (100mg/m2) (FEC-D). Cytokeratin (CK) 5/6 and EGFR expression were used to identify basal and non-basal triple-negative (TN) BC. The primary endpoint was pathological complete response (pCR); secondary endpoints were safety, breast-conserving surgery, disease-free survival, and overall survival. Predictive factors of pCR for each regimen were also evaluated.
Results:
The pCR rate was 36% for FEC-D and 25.5% for TC6, which did not differ significantly (P=0.265). When TN BC was subdivided into basal and non-basal subtypes, the pCR rate in the basal subtype was significantly lower for TC6 (13.6%) than for FEC-D (42.9%) (P=0.033), but did not significantly differ in the non-basal (TC6, 36.4%; FEC-D, 25.0%) and HER2-positive (TC6, 41.7%; FEC-D, 35.7%) cases.
The relative dose intensities of epirubicin and docetaxel in FEC-D and docetaxel in TC6 were 96.3±13.0%, 93.5±14.6%, and 93.9±16.3% (mean±SD), respectively. Occurrence of grade ≥2 adverse events was significant in FEC-D-treated patients. Poor appetite (P<0.001), nausea (P<0.001), vomiting (P<0.001), dysgeusia (P=0.03), and fatigue (P=0.05) were significantly more common for FEC-D than TC6. Patients treated with FEC-D experienced significantly more febrile neutropenia and anemia (P=0.016 and 0.017, respectively).
The rates of breast-conserving surgery were 68.0 and 72.3% for FEC-D and TC6, respectively (P=0.641).
Patients achieved pCR had better DFS (log rank test, P = 0.287) and OS (log rank test, P = 0.069), though not significant. Patients treated with FEC-D had better DFS (log rank test, P = 0.107) and OS (log rank test, P = 0.159), though not significant. Among patients with TN BC, those treated with FEC-D had significantly better DFS (log rank test, P = 0.016) and OS (log rank test, P = 0.034) than treated with TC6.
Low ALDH1 expression and high topo IIα protein expression were strongly correlated with pCR in FEC-D, with odds ratios (ORs) of 4.33 [95% CI, 1.02–18.38] and 4.08 [0.97–17.2], respectively. ALDH1 was also associated with pCR in TC, OR=3.50 [0.84–14.6]. Other factors, including age, tumor size, nodal status, tumor grade, Ki67, p53, and TOP 2A status were not associated with pCR in either regimen.
Conclusions:We found that TC6 was less effective than FEC-D for treating HR-negative BC because it was insufficient for TNBC, particularly for basal BC. This suggests that anthracycline is more important than taxane for basal BC. Additionally, ALDH1 could be a marker for resistance to conventional chemotherapy.
Citation Format: Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- K Narui
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ishikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - D Shimizu
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Tanabe
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Sasaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - MS Oba
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Morita
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Nawata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Kida
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Mogaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Doi
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Tsugawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Ogata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ota
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Kosaka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - N Sengoku
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Kuranami
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Saito
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Suzuki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - A Suto
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Arioka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Chishima
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Ichikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - I Endo
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Tokuda
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| |
Collapse
|
22
|
Soeda E, Hoshino K, Izawa Y, Takaoka C, Isobe C, Takahashi A, Takahashi N, Yamada Y, Shimojima N, Fujino A, Shinoda M, Kitagawa Y, Tanabe M, Nakamaru S, Taki N, Sekiguchi A, Nakazawa Y, Turukawa T, Kuroda T. A Report on the Positive Response to an Outdoor Nature Challenge of a Snow Camp for Young Liver Transplant Patients. Transplant Proc 2017; 49:115-120. [PMID: 28104117 DOI: 10.1016/j.transproceed.2016.10.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVES More than two decades have passed since the first living donor liver transplantation was performed in Japan in 1989. There are many reports about problems in adherence to taking medication and medical follow-ups in children who received liver transplants, because there is no transition strategy for those children and parents or guardians. The objective of this study is to measure the effect of nature and outdoor activity to improve children's medical adherence. METHODS We recruited participants from 9-year-old children who are attending the outpatient liver transplant clinic in a stable condition (no event such as rejection or surgical procedure within 6 months). We took participants to a snow camp and measured its effect by using the IKIRU CHIKARA (IKR) tool, which contain 28 items divided into 3 categories: psychosocial ability, moral fitness, and physical ability. Children were tested on three occasions, before, just after, and 1 month after the camp. RESULTS Eight patients participated in the snow camp and 7 patients were eligible for the study. The average age was 12.6 with a range 10 to 17 years. There were 3 girls and 4 boys. The average IKR scores before, just after, and 1 month after the camp were 127.9, 131.5, and 126.6, respectively. CONCLUSION An outdoor activity such as a snow camp can be safely conducted, and it is an acceptable option to incorporate within a pediatric liver transplant program. There were no significant changes in IKR scores during this short observation. Longer observation is needed to measure the effect of nature and outdoor activities.
Collapse
Affiliation(s)
- E Soeda
- Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan.
| | - K Hoshino
- School of Medicine, Keio University, Tokyo, Japan
| | - Y Izawa
- Department of Nursing, Keio University Hospital, Tokyo, Japan
| | - C Takaoka
- Department of Nursing, Keio University Hospital, Tokyo, Japan
| | - C Isobe
- School of Nursing, Shibuya Medical Association, Tokyo, Japan
| | | | - N Takahashi
- School of Medicine, Keio University, Tokyo, Japan
| | - Y Yamada
- School of Medicine, Keio University, Tokyo, Japan
| | - N Shimojima
- School of Medicine, Keio University, Tokyo, Japan
| | - A Fujino
- School of Medicine, Keio University, Tokyo, Japan
| | - M Shinoda
- School of Medicine, Keio University, Tokyo, Japan
| | - Y Kitagawa
- School of Medicine, Keio University, Tokyo, Japan
| | - M Tanabe
- Faculty of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Nakamaru
- Faculty of Health and Sports Science, Juntendo University, Chiba, Japan
| | - N Taki
- Faculty of Educatoin, Shinshu University, Nagano, Japan
| | - A Sekiguchi
- Japanese Center for Research on Women in Sports, Juntendo University, Tokyo, Japan
| | | | | | - T Kuroda
- School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|
23
|
Suzuki T, Zeng Z, Zhao B, Wei Z, Tanabe M, Shimbo T, Kajio H, Kato N, Naruse M. Comparison of coronary heart disease risk among four diagnostic definitions of metabolic syndrome. J Endocrinol Invest 2016; 39:1337-1346. [PMID: 27572249 DOI: 10.1007/s40618-016-0538-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 08/19/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE Metabolic syndrome (MetS) is now well known as one of the major risk factors for coronary heart disease (CHD). Currently, there are several methods used to define MetS. The aim of this study was to determine to what extent current MetS definition reflects CHD risk using the probability of CHD in 10 years based on Framingham risk score algorithms. METHODS A total of 7575 adults, aged 16-93 years (2532 men and 5043 women), were recruited. We conducted a cross-sectional health survey in China using MetS criteria from four different definitions: modified National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III), International Diabetes Federation (IDF), Chinese and Japanese. RESULTS Differences in the prevalence of MetS by each definition were small in males (22.9-25.9 %), whereas in females, MetS was three times more prevalent using the IDF definition (29.1 %) versus the Japanese definition (9.7 %). Framingham risk scores in participants with MetS were significantly higher than in those without MetS by all definition criteria (p < 0.001). The CHD risk scores for participants with MetS by each definition showed similar values in males (range 11.5-12.1 %) with no significant differences among definitions. Conversely, in females with MetS the risk score for CHD was low (range 3.5-4.3 %) by each MetS definition. CONCLUSIONS These findings suggest that further studies are required to establish appropriate criteria of MetS in females.
Collapse
Affiliation(s)
- T Suzuki
- Department of Clinical Study and Informatics, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
- Department of Public Health, Kitasato University School of Medicine, 1-15-1, Minami-ku, Kitasato Sagamihara, Kanagawa, 252-0374, Japan.
| | - Z Zeng
- Department of Endocrinology, Peking Union Medical College Hospital, Beijing, 100730, China
| | - B Zhao
- Taiyuan Center for Disease Control and Prevention, Taiyuan, 030000, China
| | - Z Wei
- Taiyuan People Hospital, Taiyuan, 030000, China
| | - M Tanabe
- Department of Endocrinology and Diabetes Mellitus, Fukuoka University Hospital, Fukuoka, 814-0180, Japan
| | - T Shimbo
- Department of Clinical Study and Informatics, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan
| | - H Kajio
- Department of Diabetes and Metabolic Medicine, Center Hospital, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan
| | - N Kato
- Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan
| | - M Naruse
- Department of Endocrinology, Metabolism and Hypertension, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan.
| |
Collapse
|
24
|
Patel P, Dahab M, Tanabe M, Murphy A, Ettema L, Guy S, Roberts B. Tracking official development assistance for reproductive health in conflict-affected countries: 2002-2011. BJOG 2016; 123:1693-704. [PMID: 26817807 PMCID: PMC5066640 DOI: 10.1111/1471-0528.13851] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2015] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To provide information on trends on official development assistance (ODA) disbursement patterns for reproductive health activities in 18 conflict-affected countries. DESIGN Secondary data analysis. SAMPLE 18 conflict-affected countries and 36 non-conflict-affected countries. METHODS The Creditor Reporting System (CRS) database was analyzed for ODA disbursement for direct and indirect reproductive health activities to 18 conflict-affected countries (2002-2011). A comparative analysis was also made with 36 non-conflict-affected counties in the same 'least-developed' income category. Multivariate regression analyses examined associations between conflict status and reproductive health ODA and between reproductive needs and ODA disbursements. MAIN OUTCOME MEASURES Patterns of ODA disbursements (constant U.S. dollars) for reproductive health activities. RESULTS The average annual ODA disbursed for reproductive health to 18 conflict-affected countries from 2002 to 2011 was US$ 1.93 per person per year. There was an increase of 298% in ODA for reproductive health activities to the conflict-affected countries between 2002 and 2011; 56% of this increase was due to increases in HIV/AIDS funding. The average annual per capita reproductive health ODA disbursed to least-developed non-conflict-affected countries was 57% higher than to least-developed conflict-affected countries. Regression analyses confirmed disparities in ODA to and between conflict-affected countries. CONCLUSIONS Despite increases in ODA for reproductive health for conflict-affected countries (albeit largely for HIV/AIDS activities), considerable disparities remains. TWEETABLE ABSTRACT Study tracking 10 years of aid for reproductive aid shows major disparities for conflict-affected countries.
Collapse
Affiliation(s)
- P Patel
- Global Health and SecurityDepartment of War StudiesKing's College LondonLondonUK
| | - M Dahab
- United Nations High Commissioner for RefugeesLondonUK
| | - M Tanabe
- Reproductive Health ProgramWomen's Refugee CommissionNew YorkNYUSA
| | - A Murphy
- London School of Hygiene & Tropical MedicineLondonUK
| | - L Ettema
- Marie Stopes InternationalBrusselsBelgium
| | - S Guy
- Marie Stopes InternationalLondonUK
| | - B Roberts
- London School of Hygiene & Tropical MedicineLondonUK
| |
Collapse
|
25
|
Tanabe M, Kelly R, de Lahunta A, Duffy MS, Wade SE, Divers TJ. Verminous Encephalitis in a Horse Produced by Nematodes in the Family Protostrongylidae. Vet Pathol 2016; 44:119-22. [PMID: 17197637 DOI: 10.1354/vp.44-1-119] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Parasitic granulomatous eosinophilic inflammation was observed in the central nervous system (CNS) of a 6-month-old Arabian colt from New York state. Inflammation was associated with eggs, larvae, and adult nematodes in the cerebellum. Nematodes had histological characteristics of the superfamily Metastrongyloidea. The presence of dorsal-spined larvae in the CNS was further indicative of infection with a nematode in the family Protostrongylidae. Infections were most compatible with Parelaphostrongylus tenuis but specific diagnosis was not possible. This is the first definitive report of a protostrongylid nematode infection in a horse.
Collapse
Affiliation(s)
- M Tanabe
- Antech Diagnostics, 17672-B Cowan Avenue, Irvine, CA 92614, USA.
| | | | | | | | | | | |
Collapse
|
26
|
Tanabe M, Iwase T, Okumura Y, Yoshida A, Masuda N, Nakatsukasa K, Shien T, Tanaka S, Komoike Y, Taguchi T, Arima N, Nishimura R, Inaji H, Ishitobi M. Local recurrence risk after previous salvage mastectomy. Eur J Surg Oncol 2016; 42:980-5. [PMID: 27055945 DOI: 10.1016/j.ejso.2016.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Revised: 03/02/2016] [Accepted: 03/04/2016] [Indexed: 11/27/2022] Open
Abstract
INTRODUCTION Breast-conserving surgery is a standard treatment for early breast cancer. For ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery, salvage mastectomy is the current standard surgical procedure. However, it is not rare for patients with IBTR who have received salvage mastectomy to develop local recurrence. In this study, we examined the risk factors of local recurrence after salvage mastectomy for IBTR. PATIENTS AND METHODS A total of 118 consecutive patients who had histologically confirmed IBTR without distant metastases and underwent salvage mastectomy without irradiation for IBTR between 1989 and 2008 were included from eight institutions in Japan. The risk factors of local recurrence were assessed. RESULTS The median follow-up period from salvage mastectomy for IBTR was 4.6 years. Patients with pN2 or higher on diagnosis of the primary tumor showed significantly poorer local recurrence-free survival than those with pN0 or pN1 at primary tumor (p < 0.001). Multivariate analysis showed that the lymph node status of the primary tumor was a significantly independent predictive factor of local recurrence-free survival (p = 0.02). CONCLUSION The lymph node status of the primary tumor might be a predictive factor of local recurrence-free survival after salvage mastectomy for IBTR. Further research and validation studies are needed. (UMIN-CTR number UMIN000008136).
Collapse
Affiliation(s)
- M Tanabe
- Dept. of Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Iwase
- Dept. of Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Y Okumura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - A Yoshida
- Dept. of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan
| | - N Masuda
- Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - K Nakatsukasa
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Shien
- Dept. of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan
| | - S Tanaka
- Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan
| | - Y Komoike
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Taguchi
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - N Arima
- Dept. of Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - H Inaji
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - M Ishitobi
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
| | | |
Collapse
|
27
|
Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane. Eur J Surg Oncol 2016; 42:999-1001. [PMID: 27041672 DOI: 10.1016/j.ejso.2016.02.246] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Revised: 02/11/2016] [Accepted: 02/12/2016] [Indexed: 01/16/2023] Open
Abstract
AIM Triple negative breast cancer (TNBC) is a heterogeneous disease and is associated with the cancer stem cell (CSC), basal-like, and BRCA1 function deficient (BRCAness) subtypes. We examined these 3 subtypes in TNBC and compared their chemosensitivity against anthracycline or taxane with a special attention to BRCAness. METHODS Sixty-six TNBC cases were obtained from a randomized phase II trial comparing TCx6 (TC6) with FEC-Docetaxel (FEC-D) as neoadjuvant chemotherapy. The core needle specimens before chemotherapy were used for subtyping. The basal-like and CSC subtypes were identified by immunohistochemistry; CK5/6 and EGFR staining for the basal-like subtype and ALDH1 staining for the CSC subtype. The BRCAness subtype was examined by Multiplex Ligation-dependent Probe Amplification (MLPA). Correlations between subgroups and pCR rates according to each regimen and subtype were examined. RESULTS The basal-like and BRCAness subtypes were significantly associated (p = 0.010) with the other subtypes, but not the CSC subtype. The pCR rates were higher with FEC-D than with TC6 in the basal-like (54.5% vs 14.3%, p = 0.081) and BRCAness (56.2% vs 16.7%, p = 0.030) subtypes. Both were not effective in the CSC subtype (18.2% vs 11.8%, p = 1.00). CONCLUSION BRCAness identified by MLPA was practically useful for treatment selection for avoiding taxane. ALDH1 may be considered as a marker for the CSC subtype requiring novel agents.
Collapse
Affiliation(s)
- T Ishikawa
- Department of Breast Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo 160-0023, Japan.
| | - K Narui
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama 232-0024, Japan
| | - M Tanabe
- Department of Pathology, Yokohama City University Medical Center, Yokohama 232-0024, Japan
| | - K Kida
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama 232-0024, Japan
| | - M S Oba
- Department of Bioinformatics, Yokohama City University Medical Center, Yokohama 232-0024, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama 232-0024, Japan
| | - Y Ichikawa
- Department of Clinical Oncology and Gastrointestinal Surgery, School of Medicine, Yokohama City University, Yokohama 232-0024, Japan
| | - I Endo
- Department of Clinical Oncology and Gastrointestinal Surgery, School of Medicine, Yokohama City University, Yokohama 232-0024, Japan
| |
Collapse
|
28
|
Kimura A, Tanabe M, Tajima M, Yamazaki K. The examination of the quantification method of the physical activity of the cerebrovascular handicapped person by wearable camera. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Tanaka K, Matsuo K, Murakami T, Kawaguchi D, Hiroshima Y, Koda K, Endo I, Ichikawa Y, Taguri M, Tanabe M. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): short-term outcome, functional changes in the future liver remnant, and tumor growth activity. Eur J Surg Oncol 2015; 41:506-12. [PMID: 25704556 DOI: 10.1016/j.ejso.2015.01.031] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Revised: 01/20/2015] [Accepted: 01/23/2015] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND We compared clinical outcomes of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) against those of classical 2-stage hepatectomy in treating metastatic liver disease. METHODS Short-term outcomes, serial changes in volume of the future liver remnant (FLR), functional FLR volume, and tumor growth activity during the treatment period, were compared between our first 11 consecutive patients treated with ALPPS and 54 patients treated with classical 2-stage hepatectomy. RESULTS Mortality in the ALPPS group (9%) tended to be higher than in the classical 2-stage group (2%, P = 0.341). The FLR hypertrophy ratio (FLR volume after vs. before the procedure) 1 week after the first operation in the ALPPS group (1.54 ± 0.18) exceeded that in the classical 2-stage group (1.19 ± 0.29, P = 0.005), being similar to the ratio at 3 weeks after the first procedure in the classical 2-stage group (1.40 ± 0.43). However, functional volume of the FLR in the ALPPS group 1 week after the first procedure (52.1%) tended to be smaller than that in the classical group 3 weeks after the first procedure (59.2%). CONCLUSIONS ALPPS should be used with extreme caution, giving special attention to postoperative complications and grade of functional liver regeneration.
Collapse
Affiliation(s)
- K Tanaka
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
| | - K Matsuo
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - T Murakami
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - D Kawaguchi
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - Y Hiroshima
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - K Koda
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Y Ichikawa
- Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - M Taguri
- Department of Biostatistics and Epidemiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - M Tanabe
- Division of Diagnostic Pathology, Yokohama City University Medical Center, Yokohama, Japan
| |
Collapse
|
30
|
Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Tanaka S, Arima N, Komoike Y, Taguchi T, Iwase T, Inaji H, Ishitobi M. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. Eur J Surg Oncol 2015; 41:548-52. [PMID: 25682910 DOI: 10.1016/j.ejso.2015.01.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 01/07/2015] [Accepted: 01/19/2015] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. PATIENTS AND METHODS A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. RESULTS There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test). CONCLUSION An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.
Collapse
Affiliation(s)
- Y Okumura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - K Nakatsukasa
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - A Yoshida
- Dept. of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan
| | - N Masuda
- Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Tanabe
- Division of Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Shien
- Dept. of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan
| | - S Tanaka
- Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan
| | - N Arima
- Dept. of Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - Y Komoike
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Taguchi
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Iwase
- Division of Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - H Inaji
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - M Ishitobi
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
| | | |
Collapse
|
31
|
Kida K, Ishikawa T, Yamada A, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y, Endo I. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer. Eur J Surg Oncol 2015; 41:566-70. [PMID: 25650249 DOI: 10.1016/j.ejso.2014.10.066] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 10/08/2014] [Accepted: 10/17/2014] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Although sentinel lymph node biopsy (SLNB) is a standard staging method for assessing nodal status of breast cancer patients, SLNB after neoadjuvant chemotherapy (NAC) remains controversial. The aim of this study was to validate the practicality and accuracy of SLNB by our modified Indigocarmine blue dye methods following NAC. METHODS One hundred consecutive cases with breast cancers treated by NAC were enrolled in this study. After NAC, all patients underwent SLNB performed by our modified Indigocarmine blue dye methods without radioisotope, followed by back-up axillary lymph node dissection (ALND). RESULTS Sentinel nodes (SNs) were identified in 94 cases (identification rate, 94%); the accuracy was 94.7% (89/94 cases); and the false negative rate (FNR) 13.5% (5/37 cases). For cases with vs. without clinically evident metastatic nodes before NAC, the identification rate was 92.4% (61/66 cases) vs. 97.1% (33/34 cases); the accuracy 91.8% (56/61 cases) vs. 97.0% (32/33 cases) and the FNR 16.1% (5/31 cases) vs. 0% (0/6 case), respectively. There were six patients without identified SNs, three of them had metastatic nodes. False negatives occurred in five cases; in four, fewer than two sentinel nodes had been removed. CONCLUSION Following NAC, the accuracy of SLNB by modified Indigocarmine blue dye methods is adequate compared with other tracers. In patients in whom no SNs have been identified, lymphatic metastasis is likely and therefore ALND is recommended. For patients with cN0 prior to NAC, SLNB by modified Indigocarmine blue dye methods is clinically feasible, though controversial for patients with positive nodes.
Collapse
Affiliation(s)
- K Kida
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
| | - T Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - D Shimizu
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - M Tanabe
- Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
| | - T Sasaki
- Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
| | - Y Ichikawa
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
32
|
Narui K, Ishikawa T, Satake T, Adachi S, Yamada A, Shimada K, Shimizu D, Kida K, Sugae S, Ichikawa Y, Tanabe M, Sasaki T, Endo I. Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy. Eur J Surg Oncol 2014; 41:94-9. [PMID: 25245538 DOI: 10.1016/j.ejso.2014.09.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Revised: 08/15/2014] [Accepted: 09/01/2014] [Indexed: 10/24/2022] Open
Abstract
BACKGROUND The impact of neoadjuvant chemotherapy (NACT) on immediate free flap breast reconstruction remains controversial. Furthermore, the oncological outcomes of immediate free flap breast reconstruction after skin-sparing mastectomy (SSM) following NACT remain unclear. This study aimed to investigate the surgical complications and oncological outcomes of immediate perforator flap reconstruction after SSM following NACT. METHODS A total of 201 consecutive patients with indications for immediate perforator flap reconstruction after SSM were included between 2004 and 2012. Surgical and oncological outcomes were compared between patients with and without NACT. RESULTS There were 38 patients in the NACT group and 163 in the non-NACT control group. The median age of the NACT group was 39.5 years, which was significantly younger than the control group (43.0 years; P < 0.05). Patients in the NACT group also had more advanced and aggressive disease (P < 0.05). There was no significant difference in the frequency of surgical complications between the groups, no difference in the type of complications, and no significant difference in the frequencies of major and minor complications. No patients in the NACT group had delayed adjuvant therapy. Eight patients (4%) developed recurrences, with a median follow-up time of 3.0 years. Local recurrences occurred in three control patients but no patients in the NACT group. CONCLUSION NACT does not affect short-term or interim outcomes after immediate perforator flap reconstruction and may thus represent a safe and practical treatment option for the multidisciplinary treatment of breast cancer.
Collapse
Affiliation(s)
- K Narui
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan.
| | - T Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Satake
- Department of Plastic Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - S Adachi
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - A Yamada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - K Shimada
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - D Shimizu
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - K Kida
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - S Sugae
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Y Ichikawa
- Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - M Tanabe
- Department of Pathology, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - T Sasaki
- Department of Pathology, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
| | - I Endo
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| |
Collapse
|
33
|
Shinoda M, Tanabe M, Itano O, Obara H, Kitago M, Abe Y, Hibi T, Yagi H, Fujino A, Kawachi S, Hoshino K, Kuroda T, Kitagawa Y. Left-Side Hepatectomy in Living Donors: Through a Reduced Upper-Midline Incision for Liver Transplantation. Transplant Proc 2014; 46:1400-6. [DOI: 10.1016/j.transproceed.2013.12.061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 10/23/2013] [Accepted: 12/16/2013] [Indexed: 12/07/2022]
|
34
|
Ochiai T, Shioya A, Honma H, Saitoh Y, Matsumura S, Ban D, Irie T, Kudo A, Nakamura N, Fujikawa T, Itai A, Tanaka S, Arii S, Yamaoka S, Tanabe M. Combination Treatment of IκB Kinase β Inhibitor IMD-0354 and Gemcitabine Suppresses Oncogenic Proliferation of Pancreatic Cancer Cells. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Nishiyama R, Shinoda M, Tanabe M, Oshima G, Takano K, Miyasho T, Fuchimoto Y, Yamada S, Inoue T, Shimada K, Suda K, Tanaka M, Hayashida T, Yagi H, Kitago M, Obara H, Itano O, Takeuchi H, Kawachi S, Maruyama I, Kitagawa Y. Hemoadsorption of high-mobility group box chromosomal protein 1 using a column for large animals. Eur Surg Res 2014; 51:181-190. [PMID: 24434684 DOI: 10.1159/000357563] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Accepted: 11/22/2013] [Indexed: 09/13/2023]
Abstract
BACKGROUND High-mobility group box chromosomal protein 1 (HMGB1) has recently been identified as an important mediator of various kinds of acute and chronic inflammation. A method for efficiently removing HMGB1 from the systemic circulation could be a promising therapy for HMGB1-mediated inflammatory diseases. MATERIALS AND METHODS In this study, we produced a new adsorbent material by chemically treating polystyrene fiber. We first determined whether the adsorbent material efficiently adsorbed HMGB1 in vitro using a bovine HMGB1 solution and a plasma sample from a swine model of acute liver failure. We then constructed a column by embedding fabric sheets of the newly developed fibers into a cartridge and tested the ability of the column to reduce plasma HMGB1 levels during a 4-hour extracorporeal hemoperfusion in a swine model of acute liver failure. RESULTS The in vitro adsorption test of the new fiber showed high performance for HMGB1 adsorption (96% adsorption in the bovine HMGB1 solution and 94% in the acute liver failure swine plasma, 2 h incubation at 37°C; p < 0.05 vs. incubation with no adsorbent). In the in vivo study, the ratio of the HMGB1 concentration at the outlet versus the inlet of the column was significantly lower in swine hemoperfused with the newly developed column (53 and 61% at the beginning and end of perfusion, respectively) than in those animals hemoperfused with the control column (94 and 93% at the beginning and end of perfusion, respectively; p < 0.05). Moreover, the normalized plasma level of HMGB1 was significantly lower during perfusion with the new column than with the control column (p < 0.05 at 1, 2, and 3 h after initiation of perfusion). CONCLUSION These data suggest that the newly developed column has the potential to effectively adsorb HMGB1 during hemoperfusion in swine.
Collapse
Affiliation(s)
- R Nishiyama
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Egawa H, Teramukai S, Haga H, Tanabe M, Mori A, Ikegami T, Kawagishi N, Ohdan H, Kasahara M, Umeshita K. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant 2014; 14:102-14. [PMID: 24279828 DOI: 10.1111/ajt.12520] [Citation(s) in RCA: 126] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Revised: 09/24/2013] [Accepted: 09/24/2013] [Indexed: 01/25/2023]
Abstract
We evaluated the effects of rituximab prophylaxis on outcomes of ABO-blood-type-incompatible living donor liver transplantation (ABO-I LDLT) in 381 adult patients in the Japanese registry of ABO-I LDLT. Patients underwent dual or triple immunosuppression with or without B cell desensitization therapies such as plasmapheresis, splenectomy, local infusion, intravenous immunoglobulin and rituximab. Era before 2005, intensive care unit-bound status, high Model for End-Stage Liver Disease score and absence of rituximab prophylaxis were significant risk factors for overall survival and antibody-mediated rejection (AMR) in the univariate analysis. After adjustment for era effects in the multivariate analysis, only absence of rituximab prophylaxis was a significant risk factor for AMR, and there were no significant risk factors for survival. Rituximab prophylaxis significantly decreased the incidence of AMR, especially hepatic necrosis (p < 0.001). In the rituximab group, other B cell desensitization therapies had no add-on effects. Multiple or large rituximab doses significantly increased the incidence of infection, and early administration had no advantage. In conclusion, outcomes in adult ABO-I LDLT have significantly improved in the latest era coincident with the introduction of rituximab.
Collapse
Affiliation(s)
- H Egawa
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ishikawa T, Shimizu D, Tanabe M, Oba MS, Sasaki T, Morita S, Kida K, Nawata S, Mogami M, Doi T, Tsugawa K, Ogata H, Kosaka Y, Sengoku N, Saito Y, Suzuki Y, Suto A, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P3-14-08: A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taxane-based regimens have been developed and used widely to treat breast cancer. It has therefore become important to identify subgroups of patients in which anthracyclines are indispensable. Pathological response to neoadjuvant chemotherapy (NAC) predicts prognosis in hormone-negative subtypes. We therefore initiated a randomized phase II NAC study to compare a taxane with and without an anthracycline in these breast-cancer subtypes.
Aim: To determine the safety and activity of six cycles of docetaxel and cyclophosphamide (TC6) compared with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D), and to examine the predictive factors for each regimen.
Methods: Eligibility criteria were operable hormone-receptor-negative breast cancer, age younger than 75 years and ECOG PS0-1. According to HER2 status, patients were randomly assigned to TC (75/600 mg/m2) every 3 weeks X 6 or FEC (500/100/500 mg/m2) every 3 weeks X 3 followed by D (100 mg/m2) every 3 weeks X 3. The primary endpoint was the rate of pathological complete response (pCR; grade 3). Triple-negative (TN) breast cancer was subdivided by cytokeratin 5/6 and epidermal growth factor receptor into basal- and non-basal subtypes. Secondary endpoints were safety, breast-conserving surgery, disease-free survival, overall survival, and predictive factors: Ki-67, p53, aldehyde dehydrogenase (ALDH) 1 and topoisomerase 2A by both immunohistochemistry and fluorescence in situ hybridization for each regimen.
Results: Ninety-seven of 103 patients were analyzed successfully (50 for FEC-D and 47 for TC6). Significantly more severe adverse events (grade 2) were observed in FEC-D-treated patients (poor appetite, nausea and vomiting: p = 0.001; febrile neutropenia: p = 0.016). The pCR rate tended to be higher in FEC-D-treated patients compared with TC6-treated patients (pCR: 36.0 vs. 25.5%, n.s.). FEC-D treatment was significantly more effective than TC6 in basal-type (p = 0.033) but not in non-basal and HER2 subtypes. ALDH1 was associated with resistance to both regimens (FEC-D: p = 0.047, TC6: p = 0.085)
Conclusions: TC6 was safer, but not more effective than FEC-D. TC6 was significantly less active than FEC-D in basal subtype, and equivalent to FEC-D in HER2 and non-basal subtypes. Concurrent use of trastuzumab with TC could thus represent a reasonable option for NAC in HER2-subtype patients. ALDH1 could provide a marker for novel strategies such as stem cell-based therapies for breast cancer. Analyses on pathological factors in surgical specimens after NAC will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-08.
Collapse
Affiliation(s)
- T Ishikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - D Shimizu
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Tanabe
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - MS Oba
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Sasaki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Morita
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Kida
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Nawata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Mogami
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Doi
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Tsugawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - H Ogata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Kosaka
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - N Sengoku
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Saito
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Suzuki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Suto
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Chishima
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Ichikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - I Endo
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Tokuda
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| |
Collapse
|
38
|
Shiraga H, Fujioka S, Nakai M, Watari T, Nakamura H, Arikawa Y, Hosoda H, Nagai T, Koga M, Kikuchi H, Ishii Y, Sogo T, Shigemori K, Nishimura H, Zhang Z, Tanabe M, Ohira S, Fujii Y, Namimoto T, Sakawa Y, Maegawa O, Ozaki T, Tanaka K, Habara H, Iwawaki T, Shimada K, Key M, Norreys P, Pasley J, Nagatomo H, Johzaki T, Sunahara A, Murakami M, Sakagami H, Taguchi T, Norimatsu T, Homma H, Fujimoto Y, Iwamoto A, Miyanaga N, Kawanaka J, Kanabe T, Jitsuno T, Nakata Y, Tsubakimoto K, Sueda K, Kodama R, Kondo K, Morio N, Matsuo S, Kawasaki T, Sawai K, Tsuji K, Murakami H, Sarukura N, Shimizu T, Mima K, Azechi H. Implosion and heating experiments of fast ignition targets by Gekko-XII and LFEX lasers. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20135901008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Nasu K, Oikawa Y, Kadotani M, Tanabe M, Takeda Y, Kawaguchi R, Serikawa T, Mibiki Y, Suzuki T, Tsuji T. Everolimus and paclitaxel-eluting stents for small coronary artery diseases: insight from the one year results of PLUM and SACRA registries. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Fujita T, Tanabe M, Takahashi S, Iida E, Matsunaga N. Percutaneous transhepatic hybrid biliary endoprostheses using both plastic and metallic stents for palliative treatment of malignant common bile duct obstruction. Eur J Cancer Care (Engl) 2013; 22:782-8. [PMID: 23834370 DOI: 10.1111/ecc.12088] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/29/2013] [Indexed: 01/29/2023]
Abstract
To evaluate clinical safety and efficacy of percutaneous transhepatic hybrid biliary prostheses for palliative treatment in patients with common bile duct obstruction caused by advanced malignancies. A total of 13 consecutive patients was treated with percutaneous transhepatic biliary endoprostheses concurrently using both plastic and metallic stents. Serum total bilirubin levels before and after stent placement were evaluated. The technical success rate, the period with no obstructive jaundice, patient survival and complications were also assessed. Median bilirubin levels decreased from 3.8 mg/dL before to 1.2 mg/dL after stent placement, and this difference was statistically significant. The median no-jaundice period after bile duct stent placement was 6.0 months (range: 2-11 months), and overall survival time was 7.0 months. Of the 13 patients, nine did not have recurrent jaundice by the time of death, whereas four (31%) had recurrent jaundice. A second intervention was performed in these four patients. A new plastic stent was placed and jaundice did not recur up to the time of death. No serious complications such as cholangitis, pancreatitis or bile duct perforation developed. Percutaneous transhepatic hybrid biliary endoprostheses using both plastic and metallic stents can be useful as non-invasive palliative treatment to relieve jaundice in patients with malignant obstructive jaundice.
Collapse
Affiliation(s)
- T Fujita
- Department of Radiology, UBE INDUSTRIES, LTD. Central Hospital, Ube, Yamaguchi, Japan
| | | | | | | | | |
Collapse
|
41
|
Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Aoyagi T, Nagahashi M, Chishima T, Sasaki T, Ichikawa Y, Takabe K, Endo I. ATP-binding Cassette Transporter ABCC11 is Highly Expressed in Aggressive Breast Cancer Subtypes and Related With Worse Disease-free Survival. J Surg Res 2013. [DOI: 10.1016/j.jss.2012.10.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
42
|
Ohnami S, Kato A, Ogawa K, Shinohara S, Ono H, Tanabe M. Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain. Br J Pharmacol 2013; 167:537-47. [PMID: 22537101 DOI: 10.1111/j.1476-5381.2012.02007.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE The analgesic action of 5-HT and noradrenaline reuptake inhibitors (SNRIs) on nociceptive synaptic transmission in the spinal cord is poorly understood. We investigated the effects of milnacipran, an SNRI, on C-fibre-evoked field potentials (FPs) in spinal long-term potentiation (LTP), a proposed synaptic mechanism of hypersensitivity, and on the FPs in a neuropathic pain model. EXPERIMENTAL APPROACH C-fibre-evoked FPs by electrical stimulation of the sciatic nerve fibres were recorded in the spinal dorsal horn of anaesthetized adult rats, and LTP was induced by high-frequency stimulation of the sciatic nerve fibres. A rat model of neuropathic pain was produced by L5 spinal nerve ligation and transection. KEY RESULTS Milnacipran produced prolonged inhibition of C-fibre-evoked FPs when applied spinally after the establishment of LTP of C-fibre-evoked FPs in naïve animals. In the neuropathic pain model, spinal administration of milnacipran clearly reduced the basal C-fibre-evoked FPs. These inhibitory effects of milnacipran were blocked by spinal administration of methysergide, a 5-HT½ receptor antagonist, and yohimbine or idazoxan, α₂-adrenoceptor antagonists. However, spinal administration of milnacipran in naïve animals did not affect the basal C-fibre-evoked FPs and the induction of spinal LTP. CONCLUSION AND IMPLICATIONS Milnacipran inhibited C-fibre-mediated nociceptive synaptic transmission in the spinal dorsal horn after the establishment of spinal LTP and in the neuropathic pain model, by activating both spinal 5-hydroxytryptaminergic and noradrenergic systems. The condition-dependent inhibition of the C-fibre-mediated transmission by milnacipran could provide novel evidence regarding the analgesic mechanisms of SNRIs in chronic pain.
Collapse
Affiliation(s)
- S Ohnami
- Laboratory of CNS Pharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Japan
| | | | | | | | | | | |
Collapse
|
43
|
Tsuyuki S, Fukui S, Watanabe A, Akune S, Tanabe M, Yoshida K. Delphinidin Induces Autolysosome as well as Autophagosome Formation and Delphinidin-Induced Autophagy Exerts a Cell Protective Role. J Biochem Mol Toxicol 2012; 26:445-53. [DOI: 10.1002/jbt.21443] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 08/12/2012] [Accepted: 09/08/2012] [Indexed: 01/22/2023]
Affiliation(s)
- Satoshi Tsuyuki
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| | - Sayuri Fukui
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| | - Akari Watanabe
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| | - Satoshi Akune
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| | - Mizuki Tanabe
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| | - Kenichi Yoshida
- Department of Life Sciences; School of Agriculture; Meiji University; Kawasaki; Kanagawa; 214-8571; Japan
| |
Collapse
|
44
|
Kohno N, Miyake M, Inoue Y, Yokoyama A, Hiwada K, Tanabe M, Yamakido M, Kyoizumi S, Akiyama M. A circulating heat-resistant mucin-like antigen in patients with lung-cancer detected by a new murine monoclonal-antibody. Int J Oncol 2012; 1:649-55. [PMID: 21584594 DOI: 10.3892/ijo.1.6.649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We discovered a circulating mucin-like antigen designated as CAM-14 detected by a new murine monoclonal antibody KL-14 (IgM). We found different heat resistant properties between serum CAM- 14 from normal individuals and from lung cancer patients. Heat treatment had less effect on the levels of CAM-14 in sera from lung cancer patients, whereas CAM-14 levels in sera from normal individuals were markedly decreased after heat treatment at tempratures > 65-degrees-C. As a serum tumor marker, CAM- 14 had only very low levels of false-positive values with a high specificity and effectively increased the positive rate for lung cancer patients when used together with carcinoembryonic antigen.
Collapse
Affiliation(s)
- N Kohno
- KITANO HOSP,TAZUKE KOFUKAI MED RES INST,DEPT THORAC SURG,KITAKU,OSAKA 530,JAPAN. RADIAT EFFECTS RES FDN,DEPT RADIAT BIOL,MINAMI KU,HIROSHIMA 732,JAPAN. HIROSHIMA UNIV,SCH MED,DEPT INTERNAL MED 2,MINAMI KU,HIROSHIMA 734,JAPAN
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Nishimura S, Tanabe M, Sakai T, Kimura K, Morizono H, Iijima K, Makita M, Iwase T, Horii R, Akiyama F. 226. Can irradiation suppress multicentric cancers in conserved breast? Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
46
|
Fayolle G, Levick W, Lajiness-O'Neill R, Fastenau P, Briskin S, Bass N, Silva M, Critchfield E, Nakase-Richardson R, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Anderson A, Peery S, Chafetz M, Maris M, Ramezani A, Sylvester C, Goldberg K, Constantinou M, Karekla M, Hall J, Edwards M, Balldin V, Strutt A, Pavlik V, Marquez de la Plata C, Cullum M, lacritz L, Reisch J, Massman P, Royall D, Barber R, Younes S, Wiechmann A, O'Bryant S, Patel K, Suhr J, Patel K, Suhr J, Chari S, Yokoyama J, Bettcher B, Karydas A, Miller B, Kramer J, Zec R, Fritz S, Kohlrus S, Robbs R, Ala T, Gifford K, Cantwell N, Romano R, Jefferson A, Holland A, Newton S, Bunting J, Coe M, Carmona J, Harrison D, Puente A, Terry D, Faraco C, Brown C, Patel A, Watts A, Kent A, Siegel J, Miller S, Ernst W, Chelune G, Holdnack J, Sheehan J, Duff K, Pedraza O, Crawford J, Terry D, Puente A, Brown C, Faraco C, Watts A, Patel A, Kent A, Siegel J, Miller L, Younes S, Hobson Balldin V, Benavides H, Johnson L, Hall J, Tshuma L, O'Bryant S, Dezhkam N, Hayes L, Love C, Stephens B, Webbe F, Allen C, Lemann E, Davis A, Pierson E, Lutz J, Piehl J, Holler K, Kavanaugh B, Tayim F, Llanes S, Mulligan K, Poston K, Riccio C, Beathard J, Cohen M, Stolberg P, Hart J, Jones W, Mayfield J, Allen D, Weller J, Dunham K, Demireva P, McInerney K, Suhr J, Dykstra J, Riddle T, Suhr J, Primus M, Riccio C, Highsmith J, Everhart D, Shadi S, Lehockey K, Sullivan S, Lucas M, Mandava S, Murphy B, Donovick P, Lalwani L, Rosselli M, Coad S, Carrasco R, Sofko C, Scarisbrick D, Golden C, Coad S, Zuckerman S, Golden C, Perna R, Loughan A, Hertza J, Brand J, Rivera Mindt M, Denney R, Schaffer S, Alper K, Devinsky O, Barr W, Langer K, Fraiman J, Scagliola J, Roman E, Martinez A, Cohen M, Dunham K, Riccio C, Martin P, Robbins J, Golden C, Axelrod B, Etherton J, Konopacki K, Moses J, Juliano A, Whiteside D, Rolin S, Widmann G, Franzwa M, Sokal B, Mark V, Doyle K, Morgan E, Weber E, Bondi M, Delano-Wood L, Grant I, Sibson J, Woods S, Andrews P, McGregor S, Golden C, Etherton J, Allen C, Cormier R, Cumley N, Elek M, Green M, Ogbeide S, Kruger A, Pacheco L, Robinson G, Welch H, Etherton J, Allen C, Cormier R, Cumley N, Kruger A, Pacheco L, Glover M, Parriott D, Jones W, Loe S, Hughes L, Natta L, Moses J, Vincent A, Roebuck-Spencer T, Bryan C, Padua M, Denney R, Moses J, Quenicka W, McGoldirck K, Bennett T, Soper H, Collier S, Connolly M, Hanratty A, Di Pinto M, Magnuson S, Dunham K, Handel E, Davidson K, Livers E, Frantz S, Allen J, Jerard T, Moses J, Pierce S, Sakhai S, Newton S, Warchol A, Holland A, Bunting J, Coe M, Carmona J, Harrison D, Barney S, Thaler N, Sutton G, Strauss G, Allen D, Hunter B, Bennett T, Quenicka W, McGoldrick K, Soper H, Sordahl J, Torrence N, John S, Gavett B, O'Bryant S, Shadi S, Denney R, Nichols C, Riccio C, Cohen M, Dennison A, Wasserman T, Schleicher-Dilks S, Adler M, Golden C, Olivier T, Schleicher-Dilks S, Golden C, LeMonda B, McGinley J, Pritchett A, Chang L, Cloak C, Cunningham E, Lohaugen G, Skranes J, Ernst T, Parke E, Thaler N, Etcoff L, Allen D, Andrews P, McGregor S, Golden C, Northington S, Daniels R, Loughan A, Perna R, Hertza J, Hochsztein N, Miles-Mason E, Granader Y, Vasserman M, MacAllister W, Casto B, Peery S, Patrick K, Hurewitz F, Chute D, Booth A, Koch C, Roid G, Balkema N, Kiefel J, Bell L, Maerlender A, Belkin T, Katzenstein J, Semerjian C, Culotta V, Band E, Yosick R, Burns T, Arenivas A, Bearden D, Olson K, Jacobson K, Ubogy S, Sterling C, Taub E, Griffin A, Rickards T, Uswatte G, Davis D, Sweeney K, Llorente A, Boettcher A, Hill B, Ploetz D, Kline J, Rohling M, O'Jile J, Holler K, Petrauskas V, Long J, Casey J, Long J, Petrauskas V, Duda T, Hodsman S, Casey J, Stricker S, Martner S, Hansen R, Ferraro F, Tangen R, Hanratty A, Tanabe M, O'Callaghan E, Houskamp B, McDonald L, Pick L, Guardino D, Pick L, Pietz T, Kayser K, Gray R, Letteri A, Crisologo A, Witkin G, Sanders J, Mrazik M, Harley A, Phoong M, Melville T, La D, Gomez R, Berthelson L, Robbins J, Lane E, Golden C, Rahman P, Konopka L, Fasfous A, Zink D, Peralta-Ramirez N, Perez-Garcia M, Puente A, Su S, Lin G, Kiely T, Gomez R, Schatzberg A, Keller J, Dykstra J, Suhr J, Feigon M, Renteria L, Fong M, Piper L, Lee E, Vordenberg J, Contardo C, Magnuson S, Doninger N, Luton L, Balkema N, Drane D, Phelan A, Stricker W, Poreh A, Wolkenberg F, Spira J, Lin G, Su S, Kiely T, Gomez R, Schatzberg A, Keller J, DeRight J, Jorgensen R, Fitzpatrick L, Crowe S, Woods S, Doyle K, Weber E, Cameron M, Cattie J, Cushman C, Grant I, Blackstone K, Woods S, Weber E, Grant I, Moore D, Roberg B, Somogie M, Thelen J, Lovelace C, Bruce J, Gerstenecker A, Mast B, Litvan I, Hargrave D, Schroeder R, Buddin W, Baade L, Heinrichs R, Thelen J, Roberg B, Somogie M, Lovelace C, Bruce J, Boseck J, Berry K, Koehn E, Davis A, Meyer B, Gelder B, Sussman Z, Espe-Pfeifer P, Musso M, Barker A, Jones G, Gouvier W, Weber E, Woods S, Grant I, Johnson V, Zaytsev L, Freier-Randall M, Sutton G, Thaler N, Ringdahl E, Allen D, Olsen J, Byrd D, Rivera-Mindt M, Fellows R, Morgello S, Wheaton V, Jaehnert S, Ellis C, Olavarria H, Loftis J, Huckans M, Pimental P, Frawley J, Welch M, Jennette K, Rinehardt E, Schoenberg M, Strober L, Genova H, Wylie G, DeLuca J, Chiaravalloti N, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Hertza J, Loughan A, Perna R, Northington S, Boyd S, Ibrahim E, Seiam A, Ibrahim E, Bohlega S, Rinehardt E, Lloyd H, Goldberg M, Marceaux J, Fallows R, McCoy K, Yehyawi N, Luther E, Hilsabeck R, Fulton R, Stevens P, Erickson S, Dodzik P, Williams R, Dsurney J, Najafizadeh L, McGovern J, Chowdhry F, Acevedo A, Bakhtiar A, Karamzadeh N, Amyot F, Gandjbakhche A, Haddad M, Taub E, Johnson M, Wade J, Harper L, Rickards T, Sterling C, Barghi A, Uswatte G, Mark V, Balkema N, Christopher G, Marcus D, Spady M, Bloom J, Wiechmann A, Hall J, Loughan A, Perna R, Hertza J, Northington S, Zimmer A, Webbe F, Miller M, Schuster D, Ebner H, Mortimer B, Webbe F, Palmer G, Happe M, Paxson J, Jurek B, Graca J, Meyers J, Lange R, Brickell T, French L, Lange R, Iverson G, Shewchuk J, Madler B, Heran M, Brubacher J, Brickell T, Lange R, Ivins B, French L, Baldassarre M, Paper T, Herrold A, Chin A, Zgaljardic D, Oden K, Lambert M, Dickson S, Miller R, Plenger P, Jacobson K, Olson K, Sutherland E, Glatts C, Schatz P, Walker K, Philip N, McClaughlin S, Mooney S, Seats E, Carnell V, Raintree J, Brown D, Hodges C, Amerson E, Kennedy C, Moore J, Schatz P, Ferris C, Roebuck-Spencer T, Vincent A, Bryan C, Catalano D, Warren A, Monden K, Driver S, Chau P, Seegmiller R, Baker M, Malach S, Mintz J, Villarreal R, Peterson A, Leininger S, Strong C, Donders J, Merritt V, Vargas G, Rabinowitz A, Arnett P, Whipple E, Schultheis M, Robinson K, Iacovone D, Biester R, Alfano D, Nicholls M, Vargas G, Rabinowitz A, Arnett P, Rabinowitz A, Vargas G, Arnett P, Klas P, Jeffay E, Zakzanis K, Vandermeer M, Jeffay E, Zakzanis K, Womble M, Rohling M, Hill B, Corley E, Considine C, Fichtenberg N, Harrison J, Pollock M, Mouanoutoua A, Brimager A, Lebby P, Sullivan K, Edmed S, Silva M, Nakase-Richardson R, Critchfield E, Kieffer K, McCarthy M, Wiegand L, Lindsey H, Hernandez M, Puente A, Noniyeva Y, Lapis Y, Padua M, Poole J, Brooks B, McKay C, Mrazik M, Meeuwisse W, Emery C, Brooks B, Mazur-Mosiewicz A, Sherman E, Brooks B, Mazur-Mosiewicz A, Kirkwood M, Sherman E, Gunner J, Miele A, Silk-Eglit G, Lynch J, McCaffrey R, Stewart J, Tsou J, Scarisbrick D, Chan R, Bure-Reyes A, Cortes L, Gindy S, Golden C, Hunter B, Biddle C, Shah D, Jaberg P, Moss R, Horner M, VanKirk K, Dismuke C, Turner T, Muzzy W, Dunnam M, Miele A, Warner G, Donnelly K, Donnelly J, Kittleson J, Bradshaw C, Alt M, Margolis S, Ostroy E, Rolin S, Higgins K, Denney R, Rolin S, Eng K, Biddle C, Akeson S, Wall J, Davis J, Hansel J, Hill B, Rohling M, Wang B, Womble M, Gervais R, Greiffenstein M, Denning J, Denning J, Schroeder R, Buddin W, Hargrave D, VonDran E, Campbell E, Brockman C, Heinrichs R, Baade L, Buddin W, Hargrave D, Schroeder R, Teichner G, Waid R, Buddin W, Schroeder R, Teichner G, Waid R, Buican B, Armistead-Jehle P, Bailie J, Dilay A, Cottingham M, Boyd C, Asmussen S, Neff J, Schalk S, Jensen L, DenBoer J, Hall S, DenBoer J, Schalk S, Jensen L, Hall S, Miele A, Lynch J, McCaffrey R, Holcomb E, Axelrod B, Demakis G, Rimland C, Ward J, Ross M, Bailey M, Stubblefield A, Smigielski J, Geske J, Karpyak V, Reese C, Larrabee G, Suhr J, Silk-Eglit G, Gunner J, Miele A, Lynch J, McCaffrey R, Allen L, Celinski M, Gilman J, Davis J, Wall J, LaDuke C, DeMatteo D, Heilbrun K, Swirsky-Sacchetti T, Lindsey H, Puente A, Dedman A, Withers K, Chafetz M, Deneen T, Denney R, Fisher J, Spray B, Savage R, Wiener H, Tyer J, Ningaonkar V, Devlin B, Go R, Sharma V, Tsou J, Golden C, Fontanetta R, Calderon C, Coad S, Golden C, Calderon C, Fontaneta R, Coad S, Golden C, Ringdahl E, Thaler N, Sutton G, Vertinski M, Allen D, Verbiest R, Thaler N, Snyder J, Kinney J, Allen D, Rach A, Young J, Crouse E, Schretlen D, Weaver J, Buchholz A, Gordon B, Macciocchi S, Seel R, Godsall R, Brotsky J, DiRocco A, Houghton-Faryna E, Bolinger E, Hollenbeck C, Hart J, Thaler N, Vertinski M, Ringdahl E, Allen D, Lee B, Strauss G, Adams J, Martins D, Catalano L, Waltz J, Gold J, Haas G, Brown L, Luther J, Goldstein G, Kiely T, Kelley E, Lin G, Su S, Raba C, Gomez R, Trettin L, Solvason H, Schatzberg A, Keller J, Vertinski M, Thaler N, Allen D, Gold J, Buchanan R, Strauss G, Baldock D, Ringdahl E, Sutton G, Thaler N, Allen D, Fallows R, Marceaux J, McCoy K, Yehyawi N, Luther E, Hilsabeck R, Etherton J, Phelps T, Richmond S, Tapscott B, Thomlinson S, Cordeiro L, Wilkening G, Parikh M, Graham L, Grosch M, Hynan L, Weiner M, Cullum C, Hobson Balldin V, Menon C, Younes S, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, Cullum M, Lacritz L, Reisch J, Massman P, Royall D, Barber R, O'Bryant S, Castro-Couch M, Irani F, Houshyarnejad A, Norman M, Peery S, Fonseca F, Bure-Reyes A, Browne B, Alvarez J, Jiminez Y, Baez V, Cortes L, Golden C, Fonseca F, Bure-Reyes A, Coad S, Alvarez J, Browne B, Baez V, Golden C, Resendiz C, Scott B, Farias G, York M, Lozano V, Mahoney M, Strutt A, Hernandez Mejia M, Puente A, Bure-Reyes A, Fonseca F, Baez V, Alvarez J, Browne B, Coad S, Jiminez Y, Cortes L, Golden C, Bure-Reyes A, Pacheco E, Homs A, Acevedo A, Ownby R, Nici J, Hom J, Lutz J, Dean R, Finch H, Pierce S, Moses J, Mann S, Feinberg J, Choi A, Kaminetskaya M, Pierce C, Zacharewicz M, Axelrod B, Gavett B, Horwitz J, Edwards M, O'Bryant S, Ory J, Gouvier W, Carbuccia K, Ory J, Carbuccia K, Gouvier W, Morra L, Garcon S, Lucas M, Donovick P, Whearty K, Campbell K, Camlic S, Donovick P, Edwards M, Balldin V, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, Cullum C, Lacritz L, Reisch J, Massman P, Barber R, Royall D, Younes S, O'Bryant S, Brinckman D, Schultheis M, Ehrhart L, Weisser V, Medaglia J, Merzagora A, Reckess G, Ho T, Testa S, Gordon B, Schretlen D, Woolery H, Farcello C, Klimas N, Thaler N, Allen D, Meyer J, Vargas G, Rabinowitz A, Barwick F, Arnett P, Womble M, Rohling M, Hill B, Corley E, Drayer K, Rohling M, Ploetz D, Womble M, Hill B, Baldock D, Ringdahl E, Sutton G, Thaler N, Allen D, Galusha J, Schmitt A, Livingston R, Stewart R, Quarles L, Pagitt M, Barke C, Baker A, Baker N, Cook N, Ahern D, Correia S, Resnik L, Barnabe K, Gnepp D, Benjamin M, Zlatar Z, Garcia A, Harnish S, Crosson B, Rickards T, Mark V, Taub E, Sterling C, Vaughan L, Uswatte G, Fedio A, Sexton J, Cummings S, Logemann A, Lassiter N, Fedio P, Gremillion A, Nemeth D, Whittington T, Hansen R, Reckow J, Ferraro F, Lewandowski C, Cole J, Lewandowski A, Spector J, Ford-Johnson L, Lengenfelder J, Genova H, Sumowski J, DeLuca J, Chiaravalloti N, Loughan A, Perna R, Hertza J, Morse C, McKeever J, Zhao L, Leist T, Schultheis M, Marcinak J, Piecora K, Al-Khalil K, Webbe F, Mulligan K, Robbins J, Berthelson L, Martin P, Golden C, Piecora K, Marcinak J, Al-Khalil K, Webbe F, Mulligan K, Stewart J, Acevedo A, Ownby R, Thompson L, Kowalczyk W, Golub S, Davis A, Lemann E, Piehl J, Rita N, Moss L, Davis A, Boseck J, Berry K, Koehn E, Meyer B, Gelder B, Davis A, Nogin R, Moss L, Drapeau C, Malm S, Davis A, Lemann E, Koehn E, Drapeau C, Malm S, Boseck J, Armstrong L, Glidewell R, Orr W, Mears G. Grand Rounds. Arch Clin Neuropsychol 2012. [DOI: 10.1093/arclin/acs070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Oshima G, Shinoda M, Tanabe M, Ebinuma H, Nishiyama R, Takano K, Yamada S, Miyasho T, Masugi Y, Matsuda S, Suda K, Fukunaga K, Matsubara K, Hibi T, Yagi H, Hayashida T, Yamagishi Y, Obara H, Itano O, Takeuchi H, Kawachi S, Saito H, Hibi T, Maruyama I, Kitagawa Y. Increased plasma levels of high mobility group box 1 in patients with acute liver failure. ACTA ACUST UNITED AC 2012; 48:154-62. [PMID: 22585050 DOI: 10.1159/000338363] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Accepted: 03/07/2012] [Indexed: 11/19/2022]
Abstract
BACKGROUND High-mobility group box 1 (HMGB1) is a monocyte-derived late-acting inflammatory mediator, which is released in conditions such as shock, tissue injury and endotoxin-induced lethality. In this study, we determined the plasma and hepatic tissue levels of HMGB1 in patients with acute liver failure (ALF). PATIENTS AND METHODS We determined the plasma levels of HMGB1 and aspartate aminotransferase (AST) in 7 healthy volunteers (HVs), 40 patients with liver cirrhosis (LC), 37 patients with chronic hepatitis (CH), 18 patients with severe acute hepatitis (AH), and 14 patients with fulminant hepatitis (FH). The 14 patients with FH were divided into two subgroups depending upon the history of plasma exchange (PE) before their plasma sample collection. The hepatic levels of HMGB1 were measured in tissue samples from 3 patients with FH who underwent living-donor liver transplantation and from 3 healthy living donors. Hepatic tissue samples were also subjected to immunohistochemical examination for HMGB1. RESULTS The plasma levels of HMGB1 (ng/ml) were higher in patients with liver diseases, especially in FH patients with no history of PE, than in HVs (0.3 ± 0.3 in HVs, 4.0 ± 2.0 in LC, 5.2 ± 2.6 in CH, 8.6 ± 4.8 in severe AH, 7.8 ± 2.7 in FH with a history of PE, and 12.5 ± 2.6 in FH with no history of PE, p < 0.05 in each comparison). There was a strong and statistically significant relationship between the mean plasma HMGB1 level and the logarithm of the mean AST level (R = 0.900, p < 0.05). The hepatic tissue levels of HMGB1 (ng/mg tissue protein) were lower in patients with FH than in healthy donors (539 ± 116 in FH vs. 874 ± 81 in healthy donors, p < 0.05). Immunohistochemical staining for HMGB1 was strong and clear in the nuclei of hepatocytes in liver sections from healthy donors, but little staining in either nuclei or cytoplasm was evident in specimens from patients with FH. CONCLUSION We confirmed that plasma HMGB1 levels were increased in patients with ALF. Based on a comparison between HMGB1 contents in normal and ALF livers, it is very likely that HMGB1 is released from injured liver tissue.
Collapse
Affiliation(s)
- G Oshima
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Shinoda M, Tanabe M, Kawachi S, Itano O, Obara H, Kitago M, Matsubara K, Shimojima N, Fuchimoto Y, Hoshino K, Kuroda T, Kitagawa Y. Video-assisted Living Donor Lateral Segmentectomy and Left Hepatectomy Through a Reduced Upper Midline Incision for Liver Transplantation. J Surg Res 2012. [DOI: 10.1016/j.jss.2011.11.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
49
|
Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, Kawachi K, Nozawa A, Chishima T, Kimura M, Ichikawa Y, Endo I. P5-13-23: Individualized Treatment Strategies for HER2−Negative Breast Cancer Subtypes. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Human epidermal growth factor receptor (HER2)-negative breast cancers are more heterogeneous than HER2−positive cancers, and tailored treatment is therefore required for luminal A and triple-negative breast cancer subtypes (LABC and TNBC). We therefore examined predictive factors for the efficacy of standard chemotherapy in LABC and TNBC subtypes.
Methods A total of 109 LABC and 61 TNBC patients were treated with standard neoadjuvant chemotherapy (NAC) consisting of an anthracycline and/or taxane. The pathological treatment response and prognosis were examined for each subtype. Expression levels of the following factors were examined in association with quasi-pathological complete response (QpCR): estrogen- and progesterone-receptor (ER and PgR) status, HER2, nuclear grade, MIB-1, p53, topoisomerase IIα (topoIIα), cytokeratin (CK) 5/6 and epidermal growth factor (EGFR).
Results QpCR rates in LABC and TNBC were 9.1% (10/109) and 54.1% (33/61), respectively. In LABC, the expression of PgR tended to be inversely associated with pathological response (p=0.087), while in TNBC, increased expression of topoIIa (p=0.006) and MIB-1 (p=0.018) were identified as predictors of QpCR. TopoIIα expression was also significantly associated with pathological response in multivariate analysis (p=0.014). The QpCR rate was higher in TNBC lacking CK5/6 and/or EGFR expression, defined as non-basal subtype (p=0.053).
Conclusions Low expression of PgR may be a possible predictor of the efficacy of chemotherapy in LABC, while a high level of proliferative activity, indicated by topoIIa and MIB-1, is associated with chemosensitivity in TNBC. Further subclassification into basaland non basal-subtypes may also be helpful for the development of individualized treatments.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-23.
Collapse
Affiliation(s)
- T Ishikawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - D Shimizu
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Yamada
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Sasaki
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Morita
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Tanabe
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Kawachi
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Nozawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Chishima
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Kimura
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Ichikawa
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| | - I Endo
- 1Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University, Yokohama, Kanagawa, Japan
| |
Collapse
|
50
|
Kotani K, Satoh-Asahara N, Kato Y, Araki R, Himeno A, Yamakage H, Koyama K, Tanabe M, Oishi M, Okajima T, Shimatsu A. Serum Amyloid a Low-Density Lipoprotein Levels and Smoking Status in Obese Japanese Patients. J Int Med Res 2011; 39:1917-1922. [DOI: 10.1177/147323001103900536] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
Abstract
Serum amyloid A low-density lipoprotein (SAA-LDL) is formed by an oxidative interaction and is considered to be a new marker related to oxidative modification of LDL. As the effect of smoking on oxidized LDL is of concern, this study investigated the association between SAA-LDL and smoking status. A total of 578 Japanese obese outpatients (mean ± SD age 50.5 ± 14.3 years) were studied. Smoking status was examined via a self-reported questionnaire. Cardiometabolic variables, including high-sensitivity C-reactive protein (hsCRP), were analysed in addition to SAA-LDL. There was an increasing trend in SAA-LDL levels from non- to ex- to current smokers, and significantly higher SAA-LDL levels were observed in current smokers versus non-smokers (median SAA-LDL level 36 μg/ml versus 28 μg/ml, respectively). This significant difference was reduced after adjusting for multiple confounders, including lipid levels. Smoking may be associated with increased levels of SAA-LDL in an obese Japanese population, but further studies are needed.
Collapse
Affiliation(s)
- K Kotani
- Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan
- Department of Clinical Laboratory Medicine, Jichi Medical University, Tochigi, Japan
| | - N Satoh-Asahara
- Division of Metabolic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan
| | - Y Kato
- Diabetes and Endocrine Centre, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan
| | - R Araki
- Internal Medicine, National Hospital Organization Mie Hospital, Mie, Japan
| | - A Himeno
- Division of Metabolic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan
| | - H Yamakage
- Division of Metabolic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan
| | - K Koyama
- Diabetes Centre, National Hospital Organization Tokyo Medical Centre, Tokyo, Japan
- International University of Health and Welfare, Mita Hospital, Tokyo, Japan
| | - M Tanabe
- Diabetes Centre, National Hospital Organization Kokura Hospital, Kitakyu-syu, Japan
| | | | - T Okajima
- Diabetes Centre, National Hospital Organization Kokura Hospital, Kitakyu-syu, Japan
| | - A Shimatsu
- Division of Metabolic Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan
| |
Collapse
|